ПРИОРИТЕТНЫЕ НАПРАВЛЕНИЯ В ЛЕЧЕНИИ МИГРЕНИ


Цитировать

Полный текст

Аннотация

Мигрень является хроническим заболеванием, нарушающим привычный образ жизни, работоспособность, приводящим к дезадаптации пациентов. Обсуждается проблема терапии и профилактики приступов мигрени. Рассматриваются лекарственные средства различных фармакологических групп, применяемые для лечения острых болевых приступов и превентивной терапии. Подчеркивается, что профилактика мигрени является одним из самых эффективных способов борьбы с этим заболеванием. Необходимость проведения превентивной терапии определяется не только частотой, длительностью и интенсивностью мигренозных приступов. Показаниями к профилактическому лечению являются: высокий уровень дезадаптации больных, наличие коморбидных расстройств, осложнения мигрени и высокий риск хронификации заболевания.

Об авторах

Г Р Табеева

ММА им. И.М. Сеченова, Москва

ММА им. И.М. Сеченова, Москва

G R Tabeeva

Список литературы

  1. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from American Migraine Study. Headache 1998;38:87-96.
  2. Lipton RB, Amatniek JC, Ferrari MD, et al. Migraine: Identifying and removing barriers to care. Neurology 1994;44(Suppl. 4):63-68.
  3. Ferrari A, Pasciullo G, Savino G, et al. Headache treatment before and after the consultation of a specialized center: a pharmacoepidemiologic study. Cephalalgia 2004;24:356-62.
  4. Wenzel RG, Schommer JC, Marks TG. Morbidity and medication preferences in individuals with headache presenting to a community pharmacy. Headache 2004;44:90-94.
  5. Malik SN, Hopkins M, Young WB, et al. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache 2006;46:773-80.
  6. Diamond ML, Wenzel RG, Nissan GR. Optimizing migraine therapy: evidence-based and patient-centered care. Expert Rev Neurother 2006;6:911-19.
  7. Landy S. Migraine throughout the life cycle. Treatment through the ages. Neurology 2004;62(Suppl. 2):2-8.
  8. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42 (Suppl. 1):3-9.
  9. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001;41:638-45.
  10. Diamond S, Bigal ME, Silberstein SD, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-63.
  11. Lucas C, Chaffaut C, Artaz MA, et al. FRAMIG 2000: Medical and therapeutic management of migraine in France. Cephalalgia 2005;25:267-79.
  12. Morillo LE, Alarson F, Aranaga N. Latin American Migraine Study Group. Clinical characteristics and patterns of medication use of migraineurs in Latin America from 12 cities in 6 countries. Headache 2005;45:118-26.
  13. Borkum JM. Elements of behavioral medicine treatment. In: Borkum JM Chronic headaches: biology, psychology, and behavioral treatment. Lawrence Erlbaum Associates 2007:321-50.
  14. Melchart D, Linde K, Fischer P. Acupuncture for idiopathic headache. Cochrane Database Syst Rev 2002;3:CD001218.
  15. van der Kuy PH, Merkus FW, Lohman JJ, et al. Hydroxycobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalagia 2002;22(7):513-19.
  16. Sandor PS, Di Clemente L, Coppola G. Efficacy of Coenzyme Q10 in migraine prophylaxis: a randomizes controlled trial. Neurology 2005;64:713-715.
  17. Hershey AD, Powers SW, Vockell ALB, et al. Coenzyme Q deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007;47:73-80.
  18. Magis D, Deprez C, Ambrosini A, et al. A randomizes, double-dlind placebo-controlled parallel group study of thioctic (or α-lipoic) acid, 600 mg p.o. in migraine prophylaxis. Cephalalgia 2001;21(4):2-129.
  19. Magis D, Ambrosini A, Sandor P, et al. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 2007;47:52-57.
  20. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43:9-15.
  21. Aurora SK, Gawel M, Brandes JL, et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47:486-99.
  22. Evers S, Olesen J. Botulinum toxin in headache treatment: the end of the road? Cephalagia 2006;26:769-71.
  23. Facchinetti F, Sances G, Borella P. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991;31:298-301.
  24. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalagia 1996;16:257-63.
  25. Tfelt-Hansen P, Olesen J. Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. Eur Neurol J 1980;19:163-65.
  26. Diamond S. Treatment of migraine with isometheptene, acetaminophen and dichlorphenazone combination: a double-blind, cross-over trial. Headache 1976;16:282-87.
  27. Peatfield RC, Petty RG, Rose FC. Double blind comparison of mefamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia 1983;3:129-34.
  28. Tfelt-Hansen P, Rolan P. Nonsteroidal anti-inflammatory drugs in the acute treatment of migraines. In: The Headaches. Olesen J., Goadsby PJ., Ramadan NM eds. 3rd ed. Lippincott Williams & Wilkins 2005;449-57.
  29. Tfelt-Hansen P, Young WB, Silberstein SD. Antiemetic, prokinetic, neuroleptic and miscellaneous drugs in the acute treatment of migraine. In: The Headaches. Olesen J., Goadsby PJ., Ramadan NM eds. 3rd ed. Lippincott Williams & Wilkins 2005;505-13.
  30. Goadsby PJ, Gundlach AL. Localization of H-dihydroergotamine binding sites in the cat central nervous system. Ann Neurol 1991;29:91-94.
  31. Dahlo C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-71.
  32. Ferrari MD, Roon KI, Lipton RB. Oral triptans - serotonin 5-HT (1B/1D) agonists - in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358(9294):1668-75.
  33. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997;17:73-80.
  34. Saper JR, Silberstein SD, Lake AE, et al. Double-blind trial of fluoxetine: chronic daily headache in migraine. Headache 1994;34:497-502.
  35. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia 1997;17:81-83.
  36. Silberstein SD, Neto W, Schmitt J, et al. MIGR-001 study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-95.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2009